Chronic allograft arteriosclerosis: Contributing factors and molecular mechanisms in the light of experimental studies

Transplant Immunology

Volumn 4, Issue 2, 1996, Pages 91-98

  Räisänen Sokolowski, Anne ^a,b   Häyry, Pekka ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ALLOGRAFT; ARTERIOSCLEROSIS; ENDOTHELIUM INJURY; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER;

EID: 0030175202     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(96)80001-3     Document Type: Article

References (87)

1. Cecka J, Terasaki P. The UNOS scientific renal transplant registry. Terasaki P, Cecka J. Clinical transplants 1993. 1993;1-18 UCLA Tissue Typing Laboratory, Los Angeles.
2. Naimark D, Cole E. Determinants of long-term renal allograft survival. Transplant Rev. 8:1994;93-113.
3. Paul LC, Hayry P, Foegh M, et al. Diagnostic criteria fro chronic rejection/accelerated graft atherosclerosis in heart and kidney transplants: joint proposal from the Fourth Alexis Carrel Conference on Chronic Rejection and Accelerated Arteriosclerosis in Transplanted Organs. Transplant Proc. 25:1993;2022-2023.
4. Demetris A.J, Zerbe T, Banner B. Morphology of solid organ allograft arteriopathy: identification of proliferating intimal cell populations. Transplant Proc. 21:1989;3667-3669.
5. Solez K, Axelsen R.A, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int. 44:1993;411-422.
6. Oguma S, Belle S, Starzl T.E, Demetris A.J. A histometric analysis of chronically rejected human liver allografts: insights into the mechanisms of bile duct loss: direct immunologic and ischemic factors. Hepatology. 9:1989;204-209.
7. Radio S.J.W, Markin R, Taylor R, McManus B, Stratta S. Vascular changes in chronic pancreas rejection [Abstract]. 1995;. In: 14th Annual Meeting of American Society of Transplant Physicians, Chicago.
8. Opelz G. Strength of HLA-A, HLA-AB, HLA-DR mismatches in relation to short- and long-term kidney graft survival. for the Collaborative Transplant Study Transplant Int. 5:1992;S621-S624. (suppl 1).
9. Takemoto S, Terasaki PI, Cecka JM, Cho Y.W, Gjertson D.W. Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. The UNOS Scientific Renal Transplant Registry N Engl J Med. 327:1992;834-839.
10. Abele R, Novick AC, Braun W.E, et al. Long-term results of renal transplantation in recipients with a functioning graft for 2 years. Transplantation. 34:1982;264-267.
11. Basadonna G.P, Matas A.J, Gillingham K.J, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation. 55:1993;993-995.
12. Tesi R.J, Henry M.L, Elkhammas E.A, Ferguson RM. Predictors of long-term primary cadaveric renal transplant survival. Clin Transplant. 7:1993;343-352.
13. Yilmaz S, Häyry P. The impact of acyte episodes of rejection on the generation of chronic rejection in rat renal allografts. Transplantation. 56:1993;1153-1156.
14. Grattan M.T, Moreno-Cabral C.E, Starnes V.A, Oyer P.E, Stinson E.B, Shumway N.E. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA. 261:1989;3561-3566.
15. Lemström K, Bruning J, Bruggeman C, Lautenschlager I, Häyry P. Cytomegalovirus infection enhances smooth muscle cell proliferation and intimal thickening of rat aortic allografts. J Clin Invest. 92:1993;549-558.
16. Koskinen P, Lemström K, Bruggeman C, Lautenschlager I, Häyry P. Acute cytomegalovirus infection induces a subendothelial inflammation (endothelialitis) in allograft vascular wall. Am J Pathol. 144:1994;41-50.
17. Lemström K, Aho P, Bruggeman C, Häyry P. Cytomegalovirus infection enhances mRNA expression of platelet-derived growth factor-BB and transforming growth factor β1 in rat aortic allografts. Possible mechanism for cytomegalovirus enhanced graft arteriosclerosis. Arterioscler Thromb. 14:1994;2043-2052.
18. Speir E, Modali R, Huang E-S, et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science. 265:1994;391-393.
19. Calne R, White D, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. ii:1978;1323-1328.
20. Van Son W, The T. Cytomegalovirus infection after transplantation: an update. Transplant Int. 2:1989;147-164.
21. Koskinen P, Lemström K, Häyry P. How cyclosporine modifies histological and molecular events in the vascular wall during chronic rejection of rat cardiac allografts. Am J Pathol. 146:1995;972-980.
22. MacDonald A.S, Sabr K, MacAuley M.A, McAlister VC, Bitter Suermann H, Lee T. Effects of leflunomide and cyclosporine on aortic allograft chronic rejection in the rat. Transplant Proc. 26:1994;3244-3245.
23. Cho Y, Terasaki P, Graver B. Fifteen-year kidney graft survival. Terasaki P. Clinical transplant 1989. 1989;325-334 UCLA Tissue Typing Laboratory, Los Angeles, CA.
24. Yilmaz S, Paavonen T, Häyry P. Chronic rejection of rat and allografts. II. The impact of prolonged ischemia time on transplant histology. Transplantation. 53:1992;823-827.
25. Wanders A, Akyürek M, Waltenberger J, et al. Ischemia induced transplant arteriosclerosis in the rat. Arterioscler Thromb Vasc Biol. 15:1995;145-155.
26. Land W, Schneeberger H, Schleibner S, et al. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation. 57:1994;211-217.
27. Cheigh J.S, Haschemeyer R.H, Wang JC, et al. Hypertension in kidney transplant recipients. Effect on long-term renal allograft survival. Am J Hypertens. 2:1989;341-348. (5 part 1).
28. Auersvald L, Lorber M, Friedman A, et al. Hypertension: a risk factor for chronic rejection in renal transplantation [Abstract]. First International Symposium on the Etiology and Pathobiology of Transplant Vascular Sclerosis, Bermuda. 1995.
29. Michel J-B, Plissonier D, Bruneval P. Effect of perindopril on the immune arterial wall remodeling in the rat model of arterial graft rejection. Am J Med. 92:1992;39S-46S. (Suppl 4B).
30. Report of a meeting of physicians and scientists UCLMS. Hypertriglyceridaemia and vascular risk Lancet. 342:1993;781-787.
31. Dimény E, Fellström B, Larsson E, Tufveson G, Lithell H. Chronic vascular rejection and hyperlipoproteinemia in renal transplant patients. Clin Transplant. 7:1993;482-490.
32. Dimény E. Metabolic factors and outcome of organ transplantation. Scand J Urol Nephrol Suppl. 159:1994;1-74.
33. Eich D, Thompson J, Daijin K, et al. Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary artery disease. J Heart Lung Transplant. 10:1991;45-49.
34. Higgins RM, Ratcliffe P.J. Hypercholesterolemia and vascular disease after transplantation. Transplant Rev. 3:1991;131-149.
35. Sharples L, Caine N, Mullins P, et al. Risk factor analysis for the major hazards following heart transplantation-rejection, infection, and coronary occlusive disease. Transplantation. 52:1991;244-252.
36. Billingham M.E. Cardiac transplant atherosclerosis. Transplant Proc. XIX:((4)):1987;19-25. suppl 5.
37. Scott C, Colquhoun I, Gould K, Au J, Dark J. Determinants of graft arteriosclerosis after heart transplantation. Transplant Int. 5:1992;S238-S241. (suppl 1).
38. Dimény E, Tufveson G, Lithell H, Larsson E, Siegbahn A.B.F. The influence of pretransplant lipoprotein abnormalities on the early results of renal transplantation. Eur J Clin Invest. 23:1993;572-579.
39. Räisänen-Sokolowski A, Tilly-Kiesi M, Ustinov J, et al. Hyperlipidemia accelerates allograft arteriosclerosis (chronic rejection) in the rat. Arterioscler Thromb. 14:1994;2032-2042.
40. Mahley R, Rall S.J. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism. Scriver C, Beaudet A, Sly W, Valle D. The metabolic basis of inherited disease. 1:1989;1195-1213 McGraw-Hill Information Services, New York.
41. Thyberg J, Hedin U, Sjölund M, Palmberg L, Bottger B.A. Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis. 10:1990;966-990.
42. Alonso D.R, Storek P.K, Minick R. Studies on the pathogenesis of atherosclerosis induced in rabbit cardiac allografts by the synergy of graft rejection and hypercholesterolemia. Am J Pathol. 87:1977;415.
43. Kuwahara M, Jacobson J, Kuwahara M, Kagan E, Ramwell P.W, Foegh M.L. Coronary artery ultrastructural changes in cardiac transplant atherosclerosis in the rabbit. Transplantation. 52:1991;759-765.
44. Fellström B, Dimeny E, Larsson E, Claesson K, Tufveson G. Rapidly proliferative arteriopathy in cyclosporin-induced permanently surviving rat cardiac allografts stimulating chronic vascular rejection. Clin Exp Immunol. 80:1990;288-292.
45. Tanaka H, Sukhova G.K, Libby P. Interaction of the allogeneic state and hypercholesterolemia in arterial lesion formation in experimental cardiac allografts. Arterioscler Thromb. 14:1994;734-745.
46. Mennander A.A, Tikkanen M.J, Räisänen-Sokolowski A.K, Ustinov J, Häyry P. Chronic rejection in rat allografts. IV. Effect of hypercholesterolemia in allograft arteriosclerosis. J Heart Lung Transplant. 12:1993;123-132.
47. Adams D.H, Karnovsky M.J. Hypercholesterolemia does not exacerbate arterial intimal thickening in chronically rejecting cardiac allografts. Transplant Proc. 21:1989;347.
48. Starzl T, Shapiro R, Simmons R. Atlas of organ transplantation. 1992;Gower Medical, New York.
49. Jindal R. Posttransplant diabetes mellitus - a review. Transplantation. 58:1994;1289-1298.
50. Lim E, Terasaki P. Outcome of renal transplantation in different primary disease. Terasaki PI, Cecka JM. Clinical transplants 1991. 1991;293-303 UCLA Tissue Typing Laboratory, Los Angeles, CA.
51. Heemann U.W, Azuma H, Tullius S.G, Mackenzie H, Brenner BM, Tilney N.L. The contribution of reduced functioning mass to chronic kidney allograft dysfunction in rats. Transplantation. 58:1994;1317-1322.
52. Mackenzie H.S, Tullius S.G, Heemann U.W, et al. Nephron supply is a major determinant of long-term renal allograft outcome in rats. J Clin Invest. 94:1994;2148-2152.
53. D'Alessandro A, Lorentzen D, Pirsch J, et al. Cadaveric renal transplantation in cyclosporine and OKT3 eras: an update of the University of Wisconsin-Madison experience. Terasaki P. Clinical transplants 1989. 1989;239-251 UCLA Tissue Typing Laboratory, Los Angeles.
54. Fitzpatrick M, Duffy P, Fernando O, Barratt T, Dillon M, Trompeter R. Cadaveric renal transplantation in children under 5 years of age. Pediatr Nephrol. 6:1992;166-171.
55. Häyry P. Mechanism of rejection. Curr Opin Immunol. 1:1989;1230-1235.
56. Häyry P. Aspects of allograft rejection: I: Molecular pathology of acute and chronic rejection. Transplant Rev. 9:1995;113-120.
57. Halloran P, Broski A, Batiuk T, Madrenas J. The molecular immunology of acute rejection: an overview. Transplant Immunol. 1:1993;3-27.
58. Robey E, Allison J. T-cell activation: integration of signals from the antigen receptor and costimulatory molecules. Immunol Today. 16:1995;306-310.
59. Kirby J, Wilson J. Allograft rejection: the role played by adhesion molecules. Transplant Rev. 8:1994;114-126.
60. Dallman M, Larsen C, Morris P. Cytokine gene transcription in vascularised organ grafts: analysis using semiquantitative polymerase chain reaction. J Exp Med. 174:1991;493-496.
61. Dallman M. The cytokine network and regulation of the immune response to organ transplants. Transplant Rev. 6:1992;209-217.
62. Cunningham D, Dunn M, Yacoub M, Rose M. Local production of cytokines in the human cardiac allografts. Transplantation. 57:1994;1333-1337.
63. Wu C, Kurbenov D, Lattin B, et al. Cytokine gene expression in human cardiac allograft recipients. Transplant Immunol. 2:1994;199-207.
64. Ross R, Glomset J. Atherosclerosis and the arterial smooth muscle cell. Science. 180:1973;1332-1339.
65. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1993;801-809.
66. Thyberg J, Palmberg L, Nilsson J, Ksiazek T, Sjölund M. Phenotype modulation in primary cultures of arterial smooth muscle cells. Differentiation. 25:1983;156-167.
67. Bjornsson T, Drujski M, Tluczek J, et al. Acidic fibroblast growth factor promotes vascular repair. Proc Natl Acad Sci USA. 88:1991;8651-8655.
68. Carey D. Interstitial matrix composition and function [Abstract]. 1995;. In: First International Symposium on the Etiology and Pathobiology of Transplant Vascular Sclerosis, Bermuda.
69. Klagsburn M. Tethering and release of growth factors from the interstitial matrix [Abstract]. 1995;. In: First International Symposium on the Etiology and Pathobiology of Transplant Vascular Sclerosis, Bermuda.
70. Faulk W. Alterations in hemostasis, fibrinolysis, and coagulation in transplant vascular sclerosis [Abstract]. 1995;. In: First International Symposium on the Etiology and Pathobiology of Transplant Vascular Sclerosis, Bermuda.
71. Räisänen-Sokolowski A, Vuoristo P, Myllärniemi M, Yilmaz S, Kallio E, Häyry P. Mycophenolate mofetil (MMF; RS-61443) inhibits inflammation and smooth muscle proliferation in rat aortic allografts. Transplant Immunol. 3:1995;341-350.
72. Häyry P, Räisänen A, Ustinov J, Mennander A, Paavonen T. Somatostatin analog lanreotide inhibits myocyte replication and several growth factors in allograft arteriosclerosis. FASEB J. 7:1993;1055-1060.
73. Stiles C, Capone G, Scher C, Antoniades H, Van Wyk J, Pledger W. Dual control of cell growth by somatomedins and platelet-derived growth factor. Proc Natl Acad Sci USA. 76:1979;1279-1283.
74. Grant M, Wargovich T, Ellis E, Caballero S, Mansour M, Pepine C. Localization of insulin-like growth factor 1 and inhibition of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells. Circulation. 89:1994;1511-1517.
75. Oppenheim J, Neta R. Pathophysiological roles of cytokines in development, immunity, and inflammation. FASEB J. 8:1994;158-162.
76. Sporn M, Roberts A. Peptide growth factors are multifunctional. Nature. 332:1988;217-218.
77. Banai S, Jaklitsch M, Casscells W, et al. Effect of acidid fibroblast growth factor on normal and ischemic myocardium. Circ Res. 69:1991;76-85.
78. Sato Y, Rifkin D. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol. 107:1988;1199-1205.
79. Moscatelli D, Presta M, Rifkin D. Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and migration. Proc Natl Acad Sci USA. 83:1986;2091-2095.
80. Ettenson D, Gotlieb A. Basic fibroblast growth factor is a signal for the initiation of centrosome redistribution to the front of migrating endothelial cells at the edge of an in vitro study. Arterioscler Thromb Vasc Biol. 15:1995;515-521.
81. Haudenschild C, Schwartz S. Endothelial regeneration. II. Restitution of endothelial continuity. Lab Invest. 41:1979;407-418.
82. Fellström B, Klareskog L, Heldin C.H, et al. Platelet-derived growth factor receptors in the kidney - upregulated expression in inflammation. Kidney Int. 36:1989;1099-1102.
83. Fellström B, Larsson E. Pathogenesis and treatment perspectives of chronic graft rejection (CVR). Immunol Rev. 134:1993;83-98.
84. Libby P, Salomon R, Payne D, Schoen F, Pober J. Functions of vascular wall cells related to development of transplantation-associated coronary arteriosclerosis. Transplant Proc. 21:1989;3677-3684.
85. Waltenberger J, Wanders A, Fellström B, Miyazono K, Heldin C.H, Funa K. Induction of transforming growth factor-beta during cardiac allograft rejection. J Immunol. 151:1993;1147-1157.
86. Paul L, Benediktsson H. Chronic transplant rejection: magnitude of the problem and pathogenetic mechanisms. Transplant Rev. 7:1993;96-113.
87. Noronha I, Weis H, Hartley B, Wallach D, Cameron J, Waldherr R. Expression of cytokines, growth factors, and their receptors in renal allograft biopsies. Transplant Proc. 25:1993;917-918.